ArticleMicrobial biotechnology2019
Bacteriophages engineered to display foreign peptides may become short-circulating phages.
Article in Microbial biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Antibodies targeting phage fiber and nozzle proteins impair Acinetobacter baumannii phage therapy by blocking infection and promoting immune clearance.PLoS biology · 2026Article
- Immune Responses to Phage Therapy in Humans: A Review.The Journal of infectious diseases · 2026Review
- Article
- Development of Silica Nanoparticles Embedded Adipose Spheroid Platform for Probing Bacteriophage Sequestration and Its Implications for Phage Therapy.Nanomaterials (Basel, Switzerland) · 2025Article
- Review
- Synthetic and Functional Engineering of Bacteriophages: Approaches for Tailored Bactericidal, Diagnostic, and Delivery Platforms.Molecules (Basel, Switzerland) · 2025Review
- The tumor microbiome in cancer progression: mechanisms and therapeutic potential.Molecular cancer · 2025Review
- Screening of homing and tissue-penetrating peptides by microdialysis and in vivo phage display.Life science alliance · 2025Article
- Differences in Phage Recognition and Immunogenicity Contribute to Divergent Human Immune Responses to Escherichia coli and Klebsiella pneumoniae Phages.European journal of immunology · 2025Article
- The contribution of neutrophils to bacteriophage clearance and pharmacokinetics in vivo.JCI insight · 2024Article
- Human Complement Inhibits Myophages againstViruses · 2023Article
- Bacteriophage-mediated manipulations of microbiota in gastrointestinal diseases.Frontiers in microbiology · 2022Review
- Analysis of Four NewPHAGE (New Rochelle, N.Y.) · 2021Article
- Interactions of Bacteriophages with Animal and Human Organisms-Safety Issues in the Light of Phage Therapy.International journal of molecular sciences · 2021Review
- Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Review
- Bacteriophage uptake by mammalian cell layers represents a potential sink that may impact phage therapy.iScience · 2021Article
- Phages and their potential to modulate the microbiome and immunity.Cellular & molecular immunology · 2021Review
- Modification of Bacteriophages to Increase Their Association with Lung Epithelium Cells In Vitro.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Article
- Immune Response to Therapeutic Staphylococcal Bacteriophages in Mammals: Kinetics of Induction, Immunogenic Structural Proteins, Natural and Induced Antibodies.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages draw scientific attention in medicine and biotechnology, including phage engineering, widely used to shape biological properties of bacteriophages. We developed engineered T4-derived bacteriophages presenting seven types of tissue-homing peptides. We evaluated phage accumulation in targeted tissues, spleen, liver and phage circulation in blood (in mice). Contrary to expectations, accumulation of engineered bacteriophages in targeted organs was not observed, but instead, three engineered phages achieved tissue titres up to 2 orders of magnitude lower than unmodified T4. This correlated with impaired survival of these phages in the circulation. Thus, engineering of T4 phage resulted in the short-circulating phage phenotype. We found that the complement system inactivated engineered phages significantly more strongly than unmodified T4, while no significant differences in phages' susceptibility to phagocytosis or immunogenicity were found. The short-circulating phage phenotype of the engineered phages suggests that natural phages, at least those propagating on commensal bacteria of animals and humans, are naturally optimized to escape rapid neutralization by the immune system. In this way, phages remain active for longer when inside mammalian bodies, thus increasing their chance of propagating on commensal bacteria. The effect of phage engineering on phage pharmacokinetics should be considered in phage design for medical purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.